162 related articles for article (PubMed ID: 38553623)
21. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
22. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
Mei L; Zhang J; He K; Zhang J
J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
[TBL] [Abstract][Full Text] [Related]
23. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
J Virol; 2019 May; 93(9):. PubMed ID: 30787154
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
25. Sulfoximines as ATR inhibitors: Analogs of VE-821.
Hendriks CMM; Hartkamp J; Wiezorek S; Steinkamp AD; Rossetti G; Lüscher B; Bolm C
Bioorg Med Chem Lett; 2017 Jun; 27(12):2659-2662. PubMed ID: 28479198
[TBL] [Abstract][Full Text] [Related]
26. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
[TBL] [Abstract][Full Text] [Related]
27. AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells.
Harata S; Suzuki T; Takahashi H; Hirokawa T; Kato A; Watanabe K; Yanagita T; Ushigome H; Shiga K; Ogawa R; Mitsui A; Kimura M; Matsuo Y; Takiguchi S
Oncol Rep; 2023 Mar; 49(3):. PubMed ID: 36734271
[TBL] [Abstract][Full Text] [Related]
28. IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.
O'Flanagan CH; O'Shea S; Lyons A; Fogarty FM; McCabe N; Kennedy RD; O'Connor R
Oncotarget; 2016 Aug; 7(35):56826-56841. PubMed ID: 27472395
[TBL] [Abstract][Full Text] [Related]
29. Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer.
Shao J; Huang L; Lai W; Zou Y; Zhu Q
Molecules; 2023 Jun; 28(11):. PubMed ID: 37298997
[TBL] [Abstract][Full Text] [Related]
30. Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
Jackson CB; Noorbakhsh SI; Sundaram RK; Kalathil AN; Ganesa S; Jia L; Breslin H; Burgenske DM; Gilad O; Sarkaria JN; Bindra RS
Cancer Res; 2019 Sep; 79(17):4331-4338. PubMed ID: 31273061
[TBL] [Abstract][Full Text] [Related]
31. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
Prevo R; Fokas E; Reaper PM; Charlton PA; Pollard JR; McKenna WG; Muschel RJ; Brunner TB
Cancer Biol Ther; 2012 Sep; 13(11):1072-81. PubMed ID: 22825331
[TBL] [Abstract][Full Text] [Related]
32. Requirement of MTA1 in ATR-mediated DNA damage checkpoint function.
Li DQ; Ohshiro K; Khan MN; Kumar R
J Biol Chem; 2010 Jun; 285(26):19802-12. PubMed ID: 20427275
[TBL] [Abstract][Full Text] [Related]
33. Long non-coding RNA PANDAR promoted radiation and cisplatin-induced DNA damage repair through ATR/CHK1 in NSCLC.
Zhao S; Yu N; Wang H; Wan Z; Diao C; Chen Y; Liu T; Yang Y; Gao F; Bai C; Cao K; Cai J
J Gene Med; 2023 Dec; 25(12):e3565. PubMed ID: 37460393
[TBL] [Abstract][Full Text] [Related]
34. Olaparib-induced Apoptosis Through EBNA1-ATR-p38 MAPK Signaling Pathway in Epstein-Barr Virus-positive Gastric Cancer Cells.
Moon SH; Park NS; Noh MH; Kim YS; Cheong SH; Hur DY
Anticancer Res; 2022 Jan; 42(1):555-563. PubMed ID: 34969765
[TBL] [Abstract][Full Text] [Related]
35. ATR Inhibition in Advanced Urothelial Carcinoma.
Leibrandt RC; Tu MJ; Yu AM; Lara PN; Parikh M
Clin Genitourin Cancer; 2023 Apr; 21(2):203-207. PubMed ID: 36604210
[TBL] [Abstract][Full Text] [Related]
36. New horizons in lung cancer management through ATR/CHK1 pathway modulation.
Thapa R; Afzal O; Bhat AA; Goyal A; Alfawaz Altamimi AS; Almalki WH; Alzarea SI; Kazmi I; Singh SK; Dua K; Thangavelu L; Gupta G
Future Med Chem; 2023 Oct; 15(19):1807-1818. PubMed ID: 37877252
[TBL] [Abstract][Full Text] [Related]
37. ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5‑fluorouracil by inhibiting repair of DNA damage.
Suzuki T; Hirokawa T; Maeda A; Harata S; Watanabe K; Yanagita T; Ushigome H; Nakai N; Maeda Y; Shiga K; Ogawa R; Mitsui A; Kimura M; Matsuo Y; Takahashi H; Takiguchi S
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35191521
[TBL] [Abstract][Full Text] [Related]
38. New insights into ATR inhibition in muscle invasive bladder cancer: The role of apolipoprotein B mRNA editing catalytic subunit 3B.
Kim H; Cho U; Hong SH; Park HS; Kim IH; An HJ; Shim BY; Kang JH
Oncol Res; 2024; 32(6):1021-1030. PubMed ID: 38827321
[TBL] [Abstract][Full Text] [Related]
39. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
40. P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance.
de la Cruz-Morcillo MA; Valero ML; Callejas-Valera JL; Arias-González L; Melgar-Rojas P; Galán-Moya EM; García-Gil E; García-Cano J; Sánchez-Prieto R
Oncogene; 2012 Mar; 31(9):1073-85. PubMed ID: 21841826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
